Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults
…, FH Omondi, R Kalikawe… - The Journal of …, 2022 - academic.oup.com
Background The magnitude and durability of immune responses to coronavirus disease
2019 (COVID-19) mRNA vaccines remain incompletely characterized in the elderly. Methods …
2019 (COVID-19) mRNA vaccines remain incompletely characterized in the elderly. Methods …
[HTML][HTML] Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
…, S Ennis, K Ng, S Basra, LY Lim, R Kalikawe… - npj Vaccines, 2022 - nature.com
Humoral responses to COVID-19 vaccines in people living with HIV (PLWH) remain
incompletely characterized. We measured circulating antibodies against the SARS-CoV-2 spike …
incompletely characterized. We measured circulating antibodies against the SARS-CoV-2 spike …
Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine but strong initial responses to a third dose
…, F Yaseen, G Umviligihozo, R Kalikawe… - The Journal of …, 2022 - academic.oup.com
Background Third coronavirus disease 2019 (COVID-19) vaccine doses are broadly
recommended, but immunogenicity data remain limited, particularly in older adults. Methods We …
recommended, but immunogenicity data remain limited, particularly in older adults. Methods We …
[HTML][HTML] People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose …
…, Y Sang, F Yaseen, G Umviligihozo, R Kalikawe… - medRxiv, 2022 - ncbi.nlm.nih.gov
Background: Longer-term humoral responses to two-dose COVID-19 vaccines remain
incompletely characterized in people living with HIV (PLWH), as do initial responses to a third …
incompletely characterized in people living with HIV (PLWH), as do initial responses to a third …
[HTML][HTML] Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
…, Y Baba, D Nomoto, T Yagi, R Kalikawe… - British journal of …, 2020 - nature.com
Background The PD-1/PD-L1 pathway plays critical roles in tumour immunology, and serves
as an immune-based therapeutic target. Less is known regarding PD-L2, another ligand of …
as an immune-based therapeutic target. Less is known regarding PD-L2, another ligand of …
People with human immunodeficiency virus receiving suppressive antiretroviral therapy show typical antibody durability after dual coronavirus disease 2019 …
…, F Yaseen, G Umviligihozo, R Kalikawe… - The Journal of …, 2023 - academic.oup.com
Background Longer-term humoral responses to 2-dose coronavirus disease 2019 (COVID-19)
vaccines remain incompletely characterized in people living with human …
vaccines remain incompletely characterized in people living with human …
[HTML][HTML] Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy
…, N Moran-Garcia, S Datwani, MC Duncan, R Kalikawe… - Aids, 2023 - journals.lww.com
Background: Limited data exist regarding longer term antibody responses following three-dose
coronavirus disease 2019 (COVID-19) vaccination, and the impact of a first SARS-CoV-2 …
coronavirus disease 2019 (COVID-19) vaccination, and the impact of a first SARS-CoV-2 …
[HTML][HTML] Serial infection with SARS-CoV-2 Omicron BA. 1 and BA. 2 following three-dose COVID-19 vaccination
…, PK Cheung, Y Sang, F Yaseen, R Kalikawe… - Frontiers in …, 2022 - frontiersin.org
SARS-CoV-2 Omicron infections are common among individuals who are vaccinated or
have recovered from prior variant infection, but few reports have immunologically assessed …
have recovered from prior variant infection, but few reports have immunologically assessed …
Impact of age and SARS-CoV-2 breakthrough infection on humoral immune responses after three doses of COVID-19 mRNA vaccine
…, PK Cheung, Y Sang, F Yaseen, R Kalikawe… - medRxiv, 2022 - medrxiv.org
Background Longer-term immune response data after three doses of COVID-19 mRNA
vaccine remain limited, particularly among older adults and following Omicron breakthrough …
vaccine remain limited, particularly among older adults and following Omicron breakthrough …
Older adults mount less durable humoral responses to a two-dose COVID-19 mRNA vaccine regimen, but strong initial responses to a third dose
…, Y Sang, F Yaseen, G Umviligihozo, R Kalikawe… - medRxiv, 2022 - medrxiv.org
Background Two-dose mRNA vaccines reduce COVID-19 related hospitalization and
mortality, but immune protection declines over time. As such, third vaccine doses are now …
mortality, but immune protection declines over time. As such, third vaccine doses are now …
